Virbac

Virbac EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Virbac (VIRP.PA) as of Nov 12, 2026 is 13.36. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 13.34 — a change of 0.14% (higher).

EV/EBIT

13.36

YoY

0.14%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Virbac is 2025 13.36 . EV/EBIT (Enterprise Value to EBIT) of Virbac was 2024 13.34 . It decreases by 0.14% higher compared to the previous year.

The Virbac EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
27.63 EUR
Jan 1, 2020
15.76 EUR
Jan 1, 2021
18.09 EUR
Jan 1, 2022
15.84 EUR
Jan 1, 2023
15.67 EUR
Jan 1, 2024
13.34 EUR
Jan 1, 2025
13.36 EUR
Jan 1, 2026 (e)
11.92 EUR
The Virbac EV/EBIT history
YEAREV/EBITYoY
est11.92-10.78%
13.36+0.14%
13.34-14.83%
15.67-1.11%
15.84-12.43%
18.09+14.77%
15.76-42.95%
27.63-28.42%
38.60-13.46%
44.60+2.14%
43.67-41.37%
74.49+181.81%
26.43+112.99%
12.41-1.04%
12.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Virbac Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Virbac's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Virbac's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Virbac's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Virbac grows earnings faster than its peers.

Virbac Stock analysis

What does Virbac do? Virbac SA is a French company specializing in animal medicines and care products. The company was founded in 1968 by Pierre Richard Dick, who studied veterinary medicine at the École nationale vétérinaire d'Alfort and gained experience as a veterinarian. Since its founding, Virbac SA has been headquartered near Carros, France and operates worldwide. The business model of Virbac SA is to offer a wide range of products to veterinarians and pet owners, aiming to ensure optimal health, care, and quality of life for their pets. This includes everything from vaccines, diagnostics, and medications to grooming products that veterinarians and pet owners need to ensure optimal pet healthcare. Virbac SA has five main business areas, namely livestock, pets, horses, hygiene products, and specialties. The livestock sector includes products such as feed additives and antiparasitics tailored to the specific needs of cattle, pigs, poultry, and fish. In the pets sector, Virbac SA offers products specifically tailored to dogs, cats, birds, and other pets. This includes both disease prevention and treatment products. In the horse sector, the company offers products for the maintenance, care, and health of horses. Another division of Virbac SA is hygiene products. The company offers a wide portfolio of products and solutions that support both veterinarians and pet owners in ensuring the health and care of animals. This ranges from infection control products to animal-specific shampoos and grooming items. The specialties sector, on the other hand, includes specialized products such as targeted diagnostics, therapeutics, and dietary supplements. The constant focus on research and development also leads to innovative product launches that consistently meet the highest quality standards. An example of this is the scientifically developed dental hygiene product line that improves both the oral health and breath quality of dogs and cats. For this, Virbac SA also receives awards from the Veterinary Center for Clinical Medicine in Munich. Through a systematic international expansion strategy, Virbac SA is now present in more than 100 countries. The company employs over 4,800 people worldwide and achieved a turnover of 954 million euros in 2019. Overall, Virbac SA stands for consistently high product quality and a strong customer orientation. With a combination of expertise and extensive scientific research and development, particularly in the field of animal health and care, the company is an important player in the global animal medicine manufacturing market. Virbac is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Virbac stock

EV/EBIT (Enterprise Value to EBIT) of Virbac is 13.36 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Virbac changed from 13.34 to 13.36, representing a 0.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Virbac since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Virbac with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Virbac

All Key Metrics — Virbac